Compare Sezzle Inc (SEZL) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sezzle Inc vs Vertex Pharmaceuticals Incorporated — how do they compare? Sezzle Inc trades at $128.64 (market cap $3.95B), while Vertex Pharmaceuticals Incorporated trades at $510.08 (market cap $127.55B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 32.3× Sezzle Inc's market cap, and Vertex Pharmaceuticals Incorporated is trading nearer its 52-week high, Sezzle Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Sezzle Inc for 15 Days and Vertex Pharmaceuticals Incorporated for 120 Days on average.
| SEZL | VRTX | |
|---|---|---|
Market Cap | $3.95B | $127.55B |
Volume | 550,075 | 1,487,944 |
Sector | Financials | Health |
52-Week High | $188.55 | $557.96 |
52-Week Low | $50.97 | $407.37 |
Typical Hold Time | 15 Days | 120 Days |
Enterprise Value | $3.99B | $121.68B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SEZL trades at $117.22, up 2.96% today, showing strong momentum with bullish technical indicators and trading above key support levels. The company demonstrates exceptional financial performance with 51.7% revenue growth in Q2 2026, 30.35% net income margin, and 88.85% ROE. Recent product launches including Sezzle Send and SezzleCash are driving user acquisition and platform growth.
SEZL presents a compelling growth opportunity with analyst consensus price target of $168 representing 43% upside potential. Key risks include competitive BNPL market pressures and potential credit quality concerns. The stock's premium valuation (P/E 25.71) is supported by strong earnings growth and profitability metrics, though investors should monitor execution of expansion initiatives.
Vertex Pharmaceuticals (VRTX) trades at $503.25, down 0.47% on the day, amid a bearish technical signal but strong fundamentals. The company reported $12.0B revenue and $4.0B net income for 2025, with robust profitability margins. Recent positive Phase 2b trial results for its kidney disease drug inaxaplin highlight pipeline progress. Support and resistance levels are tightly clustered around the current price, indicating potential for near-term volatility.
Outlook remains positive given dominant cystic fibrosis franchise, high margins, and promising pipeline, though earnings misses and competitive pressures pose risks. Analyst consensus is strongly bullish with a $573.50 price target, suggesting ~14% upside. Key risks include clinical trial outcomes and reliance on core franchise growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Sezzle Inc
Sezzle Inc is a financial technology company that operates a Buy Now, Pay Later (BNPL) payment platform. The company allows consumers to make purchases and split the total cost into four interest-free payments over six weeks, primarily serving the e-commerce retail market. Sezzle focuses on promoting financial empowerment by offering a transparent and responsible payment solution to customers at the point of sale.
Read more on SEZL →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
